One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment

One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment

Abstract Background The novel coronavirus is still mutating, and the pandemic continues. Meanwhile, many COVID-19 survivors have residual postinfection clinical manifestations. Human umbilical cord mesenchymal stem cells (hUC-MSCs) have been shown to be effective in the early stages of COVID-19. Obj...

Full description

Bibliographic Details
Main Authors: Lei Shi, You Zheng, Zhi Cheng, Ningfei Ji, Changming Niu, Yan Wang, Tingrong Huang, Ruyou Li, Mao Huang, Xiaolin Chen, Lei Shu, Mingjing Wu, Kaili Deng, Jing Wei, Xueli Wang, Yang Cao, Jiaxin Yan, Ganzhu Feng
Format: Article
Language:English
Published: BMC 2022-07-01
Series:Stem Cell Research & Therapy
Subjects:
Coronavirus disease 2019 (COVID-19)
Human umbilical cord mesenchymal stem cells (h-UC-MSCs)
1-Year follow-up
Sequelae
Safety
Online Access:https://doi.org/10.1186/s13287-022-02972-3

Internet

https://doi.org/10.1186/s13287-022-02972-3

Similar Items